SAC Capital

Broker's Calls

SAC Capital maintains 'buy' on Uni-Asia, citing possible recovery of charter rates

Analyst Nicole Lim notes the group’s commitment to sustainability, has target price of $1.14.
Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma - THE EDGE SINGAPORE

Broker's Calls

Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma

Although the incremental net profit contribution is likely negligible near term, the deal presents cross-selling opportunities.

Broker's Calls

Brokers' Digest: Frasers Centrepoint Trust, Japan Foods, Uni-Asia Group

See what the analysts have to say this week.

Broker's Calls

Citing big discount to book, SAC Capital maintains 'buy' on Uni-Asia

As at June 30, Uni-Asia's NAV was US$1.89, implying a price to book ratio of just 0.36x, versus a sector average of 0.92x

Broker's Calls

SAC Capital initiates 'buy' on Megachem with TP of 55 cents

The company’s sticky relationship with customers allows for high order book visibility and studier margins.
×